Tirzepatide vs Retatrutide
Tirzepatide and retatrutide are next-generation incretin-based compounds studied for metabolic research. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while retatrutide adds a third mechanism: glucagon receptor agonism.
Side-by-Side Comparison
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Category | GIP/GLP-1 dual receptor agonist (twincretin) | GIP/GLP-1/glucagon triple receptor agonist ("triple G") |
| Mechanism of Action | Activates GIP and GLP-1 receptors; stimulates insulin secretion, suppresses appetite, improves insulin sensitivity | Adds glucagon receptor agonism to the dual incretin mechanism; the glucagon component is associated with increased energy expenditure and hepatic fat mobilization in research models |
| Molecular Weight | ~4,810 Da (39 amino acids) | ~4,731 Da (39-amino-acid backbone with C-20 fatty diacid) |
| Primary Research Focus | Type 2 diabetes, obesity, cardiovascular outcomes | Obesity, type 2 diabetes, hepatic steatosis (MASLD/MAFLD) research |
| Receptor Target | GIP receptor + GLP-1 receptor | GIP receptor + GLP-1 receptor + glucagon receptor |
| Half-Life | ~5 days (C-20 fatty diacid, albumin binding) | ~6 days (fatty diacid modification, albumin binding) |
| Key Research Citations | Jastreboff et al. (2022), SURMOUNT-1, NEJM; Frias et al. (2021), SURPASS-2, NEJM | Jastreboff et al. (2023), NEJM phase 2 obesity; Rosenstock et al. (2023), Lancet phase 2 T2D |
Key Differences
- Tirzepatide activates two receptors (GIP and GLP-1); retatrutide activates three, adding the glucagon receptor to the incretin pair.
- The glucagon receptor component of retatrutide is associated with increased energy expenditure, a mechanism tirzepatide does not engage.
- In its phase 2 obesity trial, retatrutide produced up to ~24% mean body weight reduction at 48 weeks, the largest reported for an incretin-based compound at the time; tirzepatide reported up to ~21% at 72 weeks in SURMOUNT-1.
- Tirzepatide has completed phase 3 programs and extensive cardiovascular study; retatrutide remains in later-stage trials (TRIUMPH program), so its long-term dataset is smaller.
Research Summary
Tirzepatide and retatrutide represent successive generations of multi-receptor incretin pharmacology. Tirzepatide pairs GIP and GLP-1 receptor agonism and is supported by completed phase 3 programs across diabetes and obesity. Retatrutide extends the approach with glucagon receptor agonism, adding an energy-expenditure mechanism that produced the largest weight reductions reported in phase 2 obesity research. Both are lipidated 39-amino-acid peptides with multi-day half-lives suited to once-weekly protocols.
What is the difference between tirzepatide and retatrutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, while retatrutide is a triple agonist that adds glucagon receptor activation. The glucagon component is associated with increased energy expenditure, and retatrutide produced up to ~24% mean weight reduction at 48 weeks in phase 2 research versus ~21% at 72 weeks for tirzepatide in SURMOUNT-1. Tirzepatide has the more mature clinical dataset.
More Comparisons
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.